What are the treatments for CRPC after the ARPI has failed
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Treatment Options for CRPC After ARPI Failure
When castration-resistant prostate cancer (CRPC) progresses despite androgen receptor pathway inhibitors (ARPIs) like abiraterone or enzalutamide, there are several evidence-based treatment approaches. Here's what current guidelines recommend:
Standard Treatment Options
Chemotherapy
- Docetaxel remains a cornerstone option. According to NCCN Guidelines for Prostate Cancer, docetaxel is recommended for CRPC patients who have progressed on prior ARPI therapy
- Cabazitaxel (a second-generation taxane) is FDA-approved for patients who've already received docetaxel
- These work by disrupting cancer cell division
Second-Line ARPIs
- NCCN Guidelines recommend considering an alternative ARPI (switching from one to another) in selected patients, as some may still respond
- Examples include switching to abiraterone if on enzalutamide, or vice versa
Immunotherapy
- Pembrolizumab (Keytruda) received FDA approval for specific CRPC cases with microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)
- ASCO Guidelines note this is appropriate for eligible patients with these specific genetic markers
Emerging/Specialized Options
- Radium-223: For CRPC with bone metastases (spreads to bones)
- Lutetium-177 PSMA therapy: A newer nuclear medicine approach showing promise in clinical trials
- Clinical trials: Often offer access to novel combinations or newer agents
Important Considerations
According to American Cancer Society recommendations, treatment choice depends on:
- Where cancer has spread (metastatic vs. non-metastatic)
- Prior treatments received
- Your overall health and side effect tolerance
- Genetic testing results (for immunotherapy eligibility)
Next Steps: Your oncologist should discuss which option best fits your specific situation, including genetic testing if not already done, and whether clinical trials might be appropriate for you.
Would you like me to explain any of these options in more detail?
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with treatment for cancer patients
Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...
TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2